AR081049A1 - OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA - Google Patents

OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA

Info

Publication number
AR081049A1
AR081049A1 ARP100103007A AR081049A1 AR 081049 A1 AR081049 A1 AR 081049A1 AR P100103007 A ARP100103007 A AR P100103007A AR 081049 A1 AR081049 A1 AR 081049A1
Authority
AR
Argentina
Prior art keywords
treatment
farsightedness
ophthalmic
includes association
ophthalmic medicament
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Gonzalez Santos Alejandro Raul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gonzalez Santos Alejandro Raul filed Critical Gonzalez Santos Alejandro Raul
Priority to ARP100103007 priority Critical patent/AR081049A1/en
Publication of AR081049A1 publication Critical patent/AR081049A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion1: Medicamentos oftálmicos para el tratamiento de la hipermetropía incluyendo agente de accion anti-colinérgica en su formulacion. Reivindicacion 2: Medicamento oftálmico para el tratamiento de la hipermetropía incluyendo clorhidrato de pilocarpina en concentracion es de entre 0,05% a 2% en su formulacion. Reivindicacion 3: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con otro fármaco de accion adrenérgica. Reivindicacion 4: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con tetrahidrozolina entre 5 y 50 mg%. Reivindicacion 5: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con fenilefrina entre 5 y 50 mg%. Reivindicacion 6: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con nafazolina entre 1.2 y 12 mg%. Reivindicacion 7: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con oximetazolina entre 1,2 y 12 mg%.Claim 1: Ophthalmic drugs for the treatment of farsightedness including anti-cholinergic action agent in its formulation. Claim 2: Ophthalmic medicament for the treatment of farsightedness including pilocarpine hydrochloride in concentration is between 0.05% to 2% in its formulation. Claim 3: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with another adrenergic action drug. Claim 4: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with tetrahydrozoline between 5 and 50 mg%. Claim 5: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with phenylephrine between 5 and 50 mg%. Claim 6: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with nafazolin between 1.2 and 12 mg%. Claim 7: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with oxymetazoline between 1.2 and 12 mg%.

ARP100103007 2010-08-17 2010-08-17 OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA AR081049A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP100103007 AR081049A1 (en) 2010-08-17 2010-08-17 OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP100103007 AR081049A1 (en) 2010-08-17 2010-08-17 OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA

Publications (1)

Publication Number Publication Date
AR081049A1 true AR081049A1 (en) 2012-06-06

Family

ID=46379347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103007 AR081049A1 (en) 2010-08-17 2010-08-17 OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA

Country Status (1)

Country Link
AR (1) AR081049A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579308B2 (en) 2011-09-20 2017-02-28 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US10610518B2 (en) 2018-04-24 2020-04-07 Allergan, Inc. Presbyopia treatments

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579308B2 (en) 2011-09-20 2017-02-28 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US10610518B2 (en) 2018-04-24 2020-04-07 Allergan, Inc. Presbyopia treatments
US11285134B2 (en) 2018-04-24 2022-03-29 Allergan, Inc. Presbyopia treatments

Similar Documents

Publication Publication Date Title
AR121843A2 (en) OPHTHALMIC FORMULATION AND METHOD TO IMPROVE PRESBYOPIA
CL2015002680A1 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and method of using them.
CR11724A (en) AGENT TO TREAT DISEASES
CR11723A (en) AGENT TO TREAT DISEASE
DOP2012000299A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
CL2013001982A1 (en) Method to reduce glucose levels and treat metabolic disorders; pharmaceutical composition comprising metformin and another antidiabetic or antiobesity agent.
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
BR112012006283A2 (en) stabilized adamts13 formulation, method for manufacturing a stabilized adamts13 formulation, kit, and methods for treating or preventing a disease and for treating or preventing a stroke
DOP2006000057A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
AR094269A1 (en) ADDRESS DRUG TO GPC3 TO ADMINISTER A PATIENT RESPONDING TO THERAPY WITH ADDRESS DRUGS TO GPC3
BR112015005940A2 (en) process for the preparation of therapeutic nanoparticles
MX346312B (en) Ophthalmic treatments.
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
CL2010001406A1 (en) Ophthalmic pharmaceutical composition comprising povidone iodine, and a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial, an anti-allergic or an anti-glaucoma compound; and method to preserve the composition.
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
PE20140255A1 (en) DISPERSIBLE TABLET IN ORAL FORM
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
NI201400003A (en) A NEW THERAPEUTIC COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT
CO7151496A2 (en) Therapeutic agents for optimized subcutaneous administration
CO7101244A2 (en) Substituted phenylimidazopyrazoles and their use
BR112013027010A2 (en) method of producing substances with supersaturated gas, device for their transdermal delivery, and their uses
MD4538B1 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
BR112014007177A2 (en) antifungal agent

Legal Events

Date Code Title Description
FB Suspension of granting procedure